ObjectiveTo study the expression of chaperonin containing TCP-1 complex 4(CCT4) and CCT8 in hepatocellular carcinoma(HCC) and their relationship with clinical prognosis.MethodsA total of 126 patients with HCC who underwent surgical treatment in the Oncology Department of the Second Affiliated Hospital of Air Force Medical University from February 2019 to January 2021 were selected. Real-time fluorescence quantitative PCR and immunohistochemistry were used to detect the expression of CCT4 and CCT8 mRNA and protein in cancer tissues and adjacent tissues. Kaplan-Meier curve was used to analyze the effect of CCT4 and CCT8 mRNA expression on the survival and prognosis of HCC patients. Cox regression model was used to analyze the prognostic factors of HCC patients. The receiver operating characteristic(ROC) curve was used to analyze the prognostic value of CCT4 and CCT8 mRNA expression levels in HCC patients.ResultsThe positive rates of CCT4 and CCT8 in cancer tissues of HCC patients were 74.60 %(94/126) and 72.22%(91/126), respectively, which were higher than 7.94 %(10/126) and 6.35 %(8/126) in adjacent tissues(χ2=115.522,114.612, P<0.001). The relative expression levels of CCT4 and CCT8 mRNA in cancer tissues of HCC patients were higher than those in adjacent tissues(t =49.089, 57.995, P <0.001); The relative expression levels of CCT4 and CCT8 mRNA in HCC tissues with maximum tumor diameter ≥ 5 cm and CNLC stage Ⅱ-Ⅲ were higher than those with maximum tumor diameter < 5 cm and CNLC stage I(t/P=29.970/< 0.001, 20.331/<0.001, 29.046/<0.001, 20.777/< 0.001). The 3-year overall survival rate of CCT4 mRNA high expression group was 40.00%(24/60), which was lower than 63.64 %(42/66) of low expression group(Log rank χ2=9.257, P=0.002). The 3-year overall survival rate of CCT8 mRNA high expression group was 35.48%(22/62), which was lower than that of low expression group(68.75 %, 44/64)(Log rank χ2= 18.720, P<0.001). Tumor maximum diameter ≥ 5 cm, CNLC stage Ⅱ-Ⅲ, high expression of CCT4 mRNA and high expression of CCT8 mRNA were independent risk factors affecting the prognosis of HCC patients[HR( 95% CI) =1.768(1.238-2.526), 1.611(1.175-2.209), 1.859(1.330-2.599), 1.775(1.275-2.473)]. The AUC(95% CI) of blood CCT4 and CCT8 mRNA expression levels and their combined evaluation of HCC patient mortality prognosis were 0.821(0.682-0.961), 0.736(0.486-0.983), and 0.881(0.788-0.967), respectively. The AUC of their combined evaluation was greater than that of blood CCT4 and CCT8 mRNA expression levels evaluated separately(Z=3.895, 4.083, both P<0.001).ConclusionThe expression of CCT4 and CCT8 in HCC is up-regulated, which is related to CNLC stage and tumor maximum diameter. It is a risk factor affecting the prognosis of HCC. The combination of CCT4 and CCT8 has a high evaluation value for the prognosis of HCC patients.

ObjectiveTo explore the diagnostic value of magnetic resonance imaging(MRI) combined with serum C-myc and cytokeratin 19(CK19) in primary liver cancer.MethodsCase data of 86 patients with primary liver cancer(primary liver cancer group) and 71 patients with benign liver disease(benign liver disease group) admitted to our hospital from April 2022 to July 2024 were collected, and all patients underwent MRI examination. ELISA method was applied to detect the levels of serum C-myc and CK19 in patients. ROC curve was applied to analyze the diagnostic value of MRI examination parameters Kep, Ktrans, Veand serum C-myc, CK19 for primary infections. Kappa test was applied to analyze the consistency between MRI alone and in combination with serum C-myc and CK19 levels in diagnosing primary liver cancer and pathological results.ResultsThe MRI parameters Kep, Ktrans, Ve, and serum C-myc and CK19 levels in the primary liver cancer group were higher than those in the benign liver disease group(t/P=7.968/<0.001, 8.499/<0.001, 8.178/<0.001, 8.368/<0.001, 8.034/<0.001). The AUC values for diagnosing primary liver cancer using MRI parameters Kep, Ktrans, Ve,serum C-myc, CK19 alone and combined were 0.837, 0.859, 0.858, 0.804, 0.817 and 0.952, respectively(Z/P=3.059/0.002、2.658/0.008、2.687/0.007、3.847/<0.001、3.509/<0.001).The consistency test between MRI diagnosis of primary liver cancer and pathological results showed a Kappa value of 0.698(P<0.001). The consistency test between MRI combined with serum C-myc and CK19 in the diagnosis of primary liver cancer and pathological results showed a Kappa value of 0.897(P<0.001). The negative predictive value, accuracy, and sensitivity of MRI combined with serum C-myc and CK19 in the diagnosis of primary liver cancer were higher than those of MRI alone(χ2/P=9.665/0.002, 8.908/0.003, 13.526/<0.001).ConclusionMRI combined with serum C-myc and CK19 is more effective in diagnosing primary liver cancer than MRI alone, and can provide reference for early diagnosis of primary liver cancer.

ObjectiveTo explore the effectiveness and safety of using glutathione in conjunction with tenofovir disoproxil fumarate(TDF) for patients with hepatocellular carcinoma(HCC) who also have hepatitis B virus(HBV) infection, following interventional therapy.MethodsEighty-eight patients diagnosed with hepatocellular carcinoma(HCC) and hepatitis B virus(HBV) infection were selected from the patient population of hepatobiliary surgery of the Affiliated Hospital of North Sichuan Medical College between March 2022 and March 2024. These patients were randomly assigned to either the observation group(n=44) or the control group(n=44). All participants underwent trancatheter arterial chemoembolization as part of their treatment. The control group received standard continuous antiviral therapy with Tenofovir Disoproxil Fumarate(TDF), while the observation group received additional treatment with reduced glutathione in conjunction with the standard therapy. Various clinical parameters, including liver function tests [such as total bilirubin(TBil), alanine aminotransferase(ALT), and aspartate aminotransferase(AST)], coagulation function tests [including prothrombin activity(PTA), prothrombin time(PT), and activated partial thromboplastin time(APTT)], as well as nutrition-related indicators [albumin(Alb), globulin(Glb), and total protein(TP)], were evaluated in both groups before and after the treatment. Additionally, the incidence of adverse events during hospitalization and within one month after discharge was compared between the two groups.ResultsThere was no significant discrepancy in the overall clinical response rate observed between the two groups(χ2/P=0.138/0.711). Post-treatment, it was noted that the serum levels of TBil, ALT, and AST in the observation group registered a decrease in comparison to the values documented in the control group(t/P=3.258/0.002, 6.960/<0.001, 5.828/<0.001). The PTA recorded in the observation group outperformed that of the control group, with PT and APTT values being lower in the former(t/P=6.434/<0.001, 5.652/<0.001, 5.331/<0.001). no="" significant="" variance="" was="" found="" in="" glb="" levels="" post-treatment="" between="" the="" two="" p="">0.05); however, the levels of Alb and TP in the observation group demonstrated an increase over those in the control group(t/P=5.319/<0.001, 5.586/<0.001). The total incidence of adverse reactions throughout hospitalization and within 1 month after discharge showed no statistically significant difference between the two groups(χ2/P=0.386/0.534).ConclusionAdministering TDF antiviral treatment in combination with reduced glutathione to patients with HCC and HBV infection has been shown to decrease liver function impairment following interventional therapy, enhance coagulation function, and boost nutritional status. The prompt utilization of reduced glutathione holds a promising clinical outlook for HBV-infected individuals post interventional therapy for liver cancer.

Objective To investigate the value of miR-199a combined with SNAI1 detection in tumor tissues in the evaluation of colorectal cancer(CRC) disease and prognosis. Methods A total of 94 patients with CRC who were treated in the Department of General Surgery of Fengxian District Central Hospital, Shanghai from December 2018 to December 2022 were selected as the CRC group and 51 patients with benign colorectal diseases were selected as the control group. Real-time fluorescence quantitative PCR was used to detect the expression of miR-199a and SNAI1 in the two groups. Spearman rank correlation analysis was used to analyze the correlation between the expression of miR-199a and SNAI1 in CRC tumor tissues and the clinical pathological characteristics of CRC patients. Kaplan-Meier survival model was used to analyze the effect of miR-199a and SNAI1 expression on the survival and prognosis of CRC patients. Multivariate Cox regression model was used to analyze the influencing factors of CRC patients' prognosis.Results The relative expression levels of miR-199a and SNAI1 in tumor tissues of CRC group were higher than those in control group(t/P=15.129/<0.001, 12.476/<0.001). The expression levels of miR-199a and SNAI1 in tumor tissues of CRC patients with histological grade 3, T stage T3-T4, lymph node metastasis N2, distant metastasis, and TNM stage Ⅲ-Ⅳ were higher than those with histological grade 1-2, T stage T1-T2, lymph node metastasis N0-N1, no distant metastasis, and TNM stage Ⅰ-Ⅱ(miR-199a: t/P=2.002/0.048、2.095/0.039、1.995/0.049、2.003/0.048、2.933/0.004;SNAI1:t/P=2.595/0.011、3.634/<0.001、3.871/<0.001、4.975/<0.001、7.077/<0.001); The miR-199a and SNAI1 expressions in tumor tissues of CRC patients were positively correlated with histological grade, T stage, lymph node metastasis, distant metastasis, and TNM stage(miR-199a: r/P=0.643/0.038, 0.699/0.012, 0.612/0.015, 0.679/0.011, 0.654/0.019; SNAI1:r/P=0.611/0.043, 0.637/0.026, 0.644/0.017, 0.656/0.009, 0.671/0.004); The median survival of CRC patients with miR-199a≥1.68 and SNAI1≥0.96 was significantly lower than that of other patients(miR-199a<1.68 or SNAI1<0.96)(median survival 26.48±3.72 months vs. 33.81±5.59 months, Log Rank=19.141, P<0.05). The survival rate of CRC patients with miR-199a≥1.68 and SNAI1≥0.96 was significantly lower than that of other patients(miR-199a<1.68 or SNAI1<0.96)(36.25% vs. 51.17%, χ2=9.435, P<0.001). Histological grade 3, T stage T3 to T4, lymph node metastasis N2, distant metastasis, TNM stage Ⅲ to IV, elevated miR-199a, and elevated SNAI1 were independent risk factors for poor prognosis in CRC patients[HR(95%CI)=1.842(1.278-2.407), 2.004(1.129-2.879), 2.502(1.114-3.891), 3.105(1.077-5.133), 2.779(1.092-4.465), 4.586(1.566-7.607), 4.315(1.431-7.198)]. Conclusion The expression of miR-199a and SNAI1 in tumor tissues of CRC patients was significantly increased, which was associated with clinicopathological characteristics, prognosis and survival, and could be evidence at the gene level for colorectal cancer disease and prognosis evaluation. The combined detection of the two could significantly improve the clinical value in the evaluation of poor prognosis of colorectal cancer.